Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25745838 | 0.87 | PIM1 (0.38) | PIM1MEN1LMNAKMT2AFEN1 | |
| SCHEMBL25746087 | 0.86 | PIM1 (0.34) | PIM1MEN1LMNAKMT2AFEN1 | |
| SCHEMBL24815034 | 0.83 | PIM1 (0.36) | PIM1MEN1LMNAKMT2AFEN1 | |
| SCHEMBL24007975 | 0.82 | PIM1 (0.38) | PIM1MEN1LMNAKMT2AFEN1 | |
| SCHEMBL25746089 | 0.79 | CYP3A4 (0.49) | PIM1MEN1LMNAKMT2AGAA | |
| SCHEMBL26013333 | 0.78 | PIM1 (0.33) | PIM1MEN1LMNAKMT2AFEN1 | |
| SCHEMBL24007977 | 0.77 | PIM1 (0.34) | PIM1MEN1LMNAKMT2AFEN1 | |
| SCHEMBL25747186 | 0.71 | TRPV4 (0.43) | MEN1LMNAKMT2AGAA | |
| SCHEMBL10461708 | 0.69 | L3MBTL1 (0.37) | MEN1LMNAKMT2AMAPK1GAA | |
| SCHEMBL22016781 | 0.67 | BRD9 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | PIM1 844/4885MEN1 3963/4885LMNA 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.